| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Igor Dzhura, Oleg G Chepurny, Colin A Leech, Michael W Roe, Elvira Dzhura, Xin Xu, Youming Lu, Frank Schwede, Hans-G Genieser, Alan V Smrcka, George G Hol. Phospholipase C-ε links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets. vol 3. issue 3. 2011-09-27. PMID:21478675. |
glucose-stimulated insulin secretion (gsis) from pancreatic β-cells is potentiated by camp-elevating agents, such as the incretin hormone glucagon-like peptide-1 (glp-1), and camp exerts its insulin secretagogue action by activating both protein kinase a (pka) and the camp-regulated guanine nucleotide exchange factor designated as epac2. |
2011-09-27 |
2023-08-12 |
mouse |
| Yoshiro Kitahara, Kyoko Miura, Reiko Yasuda, Haruka Kawanabe, Shimpei Ogawa, Yuzuru Et. Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism. Biological & pharmaceutical bulletin. vol 34. issue 5. 2011-09-21. PMID:21532155. |
in addition, the major metabolite of nateglinide, tolbutamide, and mitiglinide, all of which augment insulin secretion by the pancreatic islets, had no effect on glp-1 release by this cell line. |
2011-09-21 |
2023-08-12 |
human |
| Yoshiro Kitahara, Kyoko Miura, Reiko Yasuda, Haruka Kawanabe, Shimpei Ogawa, Yuzuru Et. Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism. Biological & pharmaceutical bulletin. vol 34. issue 5. 2011-09-21. PMID:21532155. |
taken together, the present findings indicate that promotion of glp-1 release from intestinal l cells may be another important mechanism by which nateglinide restores early-phase insulin secretion and regulates postprandial glucose metabolism. |
2011-09-21 |
2023-08-12 |
human |
| Aurélie Waget, Cendrine Cabou, Myriam Masseboeuf, Pierre Cattan, Mattieu Armanet, Mélis Karaca, Julien Castel, Celine Garret, Gaëlle Payros, Adriano Maida, Thierry Sulpice, Jens J Holst, Daniel J Drucker, Christophe Magnan, Rémy Burceli. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology. vol 152. issue 8. 2011-09-21. PMID:21673098. |
furthermore, the dipeptides liberated from glp-1 (his-ala) and gip (tyr-ala) deteriorated glucose tolerance, reduced insulin, and increased portal glucagon levels. |
2011-09-21 |
2023-08-12 |
mouse |
| Stuart D R Galloway, Thomas P Craig, Stephen J Clelan. Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males. Amino acids. vol 41. issue 2. 2011-09-16. PMID:20963457. |
this study examined the effects of 14 days of l-carnitine l-tartrate oral supplementation (lc) on blood glucose, insulin, nefa and glp-1 responses to an oral glucose tolerance test (ogtt). |
2011-09-16 |
2023-08-12 |
human |
| Stuart D R Galloway, Thomas P Craig, Stephen J Clelan. Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males. Amino acids. vol 41. issue 2. 2011-09-16. PMID:20963457. |
on each visit, blood was drawn at rest, at intervals during the ogtt for analysis of glucose, insulin, non-esterified fatty acids (nefa) and total glucagon-like peptide-1 (glp-1). |
2011-09-16 |
2023-08-12 |
human |
| Daniel Moralejo, Ofer Yanay, Kelly Kernan, Adam Bailey, Ake Lernmark, William Osborn. Sustained glucagon-like peptide 1 expression from encapsulated transduced cells to treat obese diabetic rats. Journal of bioscience and bioengineering. vol 111. issue 4. 2011-09-15. PMID:21216666. |
glp-1 treated rats had mean insulin levels of 45.9 ± 2.3ng/ml that were significantly increased over control levels of 7.3±1.5ng/ml (p<0.001). |
2011-09-15 |
2023-08-12 |
rat |
| Kathryn M S Johnson, Tiffany Farmer, Kathleen Schurr, E Patrick Donahue, Ben Farmer, Doss Neal, Alan D Cherringto. Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog. Endocrine. vol 39. issue 3. 2011-09-02. PMID:21547512. |
antagonism of the glp-1r did not have an effect, as indicated by repeated-measures manova analysis of the Δ auc from t = 45-320 min of arterial plasma glucose, glp-1, insulin, glucagon, and acetaminophen levels. |
2011-09-02 |
2023-08-12 |
dog |
| Lora Vanis, Trygve Hausken, Diana Gentilcore, Rachael S Rigda, Christopher K Rayner, Christine Feinle-Bisset, Michael Horowitz, Karen L Jone. Comparative effects of glucose and xylose on blood pressure, gastric emptying and incretin hormones in healthy older subjects. The British journal of nutrition. vol 105. issue 11. 2011-08-26. PMID:21294929. |
a total of eight healthy older subjects (aged 65-75 years) had simultaneous measurements of bp (dinamap), ge (three-dimensional ultrasound), blood glucose, serum insulin, glp-1 and glucose-dependent insulinotropic peptide (gip), on three separate occasions, in a double-blind, randomised order. |
2011-08-26 |
2023-08-12 |
human |
| Lora Vanis, Trygve Hausken, Diana Gentilcore, Rachael S Rigda, Christopher K Rayner, Christine Feinle-Bisset, Michael Horowitz, Karen L Jone. Comparative effects of glucose and xylose on blood pressure, gastric emptying and incretin hormones in healthy older subjects. The British journal of nutrition. vol 105. issue 11. 2011-08-26. PMID:21294929. |
xylose had minimal effects on blood glucose, serum insulin or serum gip, but was more potent than glucose in stimulating glp-1 (p = 0·002). |
2011-08-26 |
2023-08-12 |
human |
| L Anzeneder, F Kircher, N Feghelm, R Fischer, J Seissle. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 43. issue 5. 2011-08-25. PMID:21448848. |
the aim of the present study was to evaluate the impact of insulin and glucagon-like peptide-1 (glp-1) secretion on early disturbance of glucose metabolism and clinical status in an unselected cohort of cf patients. |
2011-08-25 |
2023-08-12 |
human |
| L Anzeneder, F Kircher, N Feghelm, R Fischer, J Seissle. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 43. issue 5. 2011-08-25. PMID:21448848. |
we found neither a difference in basal or maximal glp-1 levels nor in insulin resistance between study groups. |
2011-08-25 |
2023-08-12 |
human |
| L Anzeneder, F Kircher, N Feghelm, R Fischer, J Seissle. Kinetics of insulin secretion and glucose intolerance in adult patients with cystic fibrosis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 43. issue 5. 2011-08-25. PMID:21448848. |
our data demonstrate that alteration of fpir, but not insulinopenia, insulin resistance, or disturbed glp-1 secretion is present in the prediabetic state in cf patients. |
2011-08-25 |
2023-08-12 |
human |
| Wendy Lane, Stephen Weinrib, Jonathan Rappapor. The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements. Diabetes technology & therapeutics. vol 13. issue 5. 2011-08-24. PMID:21406014. |
these patients would potentially benefit from the insulin-sparing and weight loss benefits of glucagon-like peptide 1 (glp-1) receptor agonist therapy; however, glp-1 receptor agonists currently are not approved for use in combination with insulin. |
2011-08-24 |
2023-08-12 |
human |
| Dorit Samocha-Bonet, Olivia Wong, Emma-Leigh Synnott, Naomi Piyaratna, Ashley Douglas, Fiona M Gribble, Jens J Holst, Donald J Chisholm, Jerry R Greenfiel. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. The Journal of nutrition. vol 141. issue 7. 2011-08-24. PMID:21593352. |
impaired glucagon-like peptide (glp-1) secretion or response may contribute to ineffective insulin release in type 2 diabetes. |
2011-08-24 |
2023-08-12 |
human |
| Dorit Samocha-Bonet, Olivia Wong, Emma-Leigh Synnott, Naomi Piyaratna, Ashley Douglas, Fiona M Gribble, Jens J Holst, Donald J Chisholm, Jerry R Greenfiel. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. The Journal of nutrition. vol 141. issue 7. 2011-08-24. PMID:21593352. |
blood was collected at baseline and postprandially for 180 min for measurement of circulating glucose, insulin, c-peptide, glucagon, and total and active glp-1. |
2011-08-24 |
2023-08-12 |
human |
| G Nicholson, G M Hal. Diabetes mellitus: new drugs for a new epidemic. British journal of anaesthesia. vol 107. issue 1. 2011-08-23. PMID:21610015. |
increased knowledge of the pathophysiology of diabetes has contributed to the development of novel treatments: glucagon-like peptide-1 (glp-1) mimetics, dipeptidyl peptidase-4 (dpp-4) inhibitors, thiazolidinediones (tzds), and insulin analogues. |
2011-08-23 |
2023-08-12 |
Not clear |
| Miriam Goebel-Stengel, Andreas Stengel, Yvette Taché, Joseph R Reev. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical biochemistry. vol 414. issue 1. 2011-08-22. PMID:21315060. |
(125)i-labeled peptides (ghrelin, sulfated cholecystokinin-8, corticotropin-releasing factor, glucagon-like peptide-1 [glp-1], insulin, leptin, nesfatin-1, and peptide yy), representing a wide spectrum in net charge, size, end group, and modification, were incubated for 48 h in glass and plastic tubes untreated or coated with siliconizing fluid. |
2011-08-22 |
2023-08-12 |
cattle |
| Dave Calabres. Differentiating incretin-based therapies for population-based health care. The American journal of managed care. vol 17. issue 2 Suppl. 2011-08-19. PMID:21517657. |
incretin hormones, such as glucagon-like peptide-1 (glp-1), play a crucial role in modulating insulin and glucagon secretion, as well as regulating appetite, gastric emptying, and pancreatic beta cell function. |
2011-08-19 |
2023-08-12 |
Not clear |
| Sanjay Kalr. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes. The Journal of the Association of Physicians of India. vol 59. 2011-08-18. PMID:21755761. |
by inhibiting dpp-4, vildagliptin causes an increase in glp-1, an intestinal hormone that aids in glucose homeostasis and insulin secretion. |
2011-08-18 |
2023-08-12 |
Not clear |